Log in

NASDAQ:TBPHTheravance Biopharma Stock Price, Forecast & News

+0.45 (+1.97 %)
(As of 04/7/2020 09:27 AM ET)
Today's Range
Now: $23.29
50-Day Range
MA: $23.72
52-Week Range
Now: $23.29
Volume327,694 shs
Average Volume429,995 shs
Market Capitalization$1.47 billion
P/E RatioN/A
Dividend YieldN/A
Theravance Biopharma, Inc., a diversified biopharmaceutical company, discovers, develops, and commercializes organ-selective medicines. The company offers VIBATIV, a bactericidal, once-daily injectable antibiotic to treat patients with serious, life-threatening infections due to staphylococcus aureus and other gram-positive bacteria, including methicillin-resistant. YUPELRI, a long-acting muscarinic antagonist, for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD); and Velusetrag, an oral and investigational medicine for gastrointestinal motility disorders. The company's product candidates also comprise Selective 5-HT4 Agonist for treating gastrointestinal motility disorders; Gut-selective Pan-Janus Kinase Inhibitor Program for treatment of rheumatoid arthritis, myelofibrosis, and ulcerative colitis; TD-9855, an investigational norepinephrine and serotonin reuptake inhibitor that has completed Phase III study for neurogenic orthostatic hypotension; and TD-0714 and Neprilysin Inhibitor Program, which have completed Phase I clinical studies for heart failure and chronic kidney disease, including diabetic nephropathy. In addition, it focuses on various drug development programs, including the combination of fluticasone furoate, umeclidinium bromide, and vilanterol for the treatment of COPD and asthma; the inhaled bifunctional muscarinic antagonist-beta2 agonist program, as monotherapy; and in combination with other therapeutically active components, such as an inhaled corticosteroid. The company was incorporated in 2013 and is based in George Town, the Cayman Islands.
Read More
Theravance Biopharma logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.4Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.36 out of 5 stars

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:TBPH
Previous SymbolNASDAQ:TBPHV



Sales & Book Value

Annual Sales$73.41 million
Book Value($3.94) per share


Net Income$-236,460,000.00
Net Margins-322.08%


Market Cap$1.47 billion
Next Earnings Date5/5/2020 (Estimated)

Receive TBPH News and Ratings via Email

Sign-up to receive the latest news and ratings for TBPH and its competitors with MarketBeat's FREE daily newsletter.

Theravance Biopharma (NASDAQ:TBPH) Frequently Asked Questions

How has Theravance Biopharma's stock been impacted by COVID-19 (Coronavirus)?

Theravance Biopharma's stock was trading at $24.80 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, TBPH stock has decreased by 6.1% and is now trading at $23.29. View which stocks have been mosted impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Theravance Biopharma?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Theravance Biopharma in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Theravance Biopharma.

When is Theravance Biopharma's next earnings date?

Theravance Biopharma is scheduled to release its next quarterly earnings announcement on Tuesday, May 5th 2020. View our earnings forecast for Theravance Biopharma.

How were Theravance Biopharma's earnings last quarter?

Theravance Biopharma Inc (NASDAQ:TBPH) posted its quarterly earnings results on Monday, February, 24th. The biopharmaceutical company reported ($1.17) earnings per share for the quarter, missing analysts' consensus estimates of ($1.11) by $0.06. The biopharmaceutical company earned $29.50 million during the quarter, compared to the consensus estimate of $18.33 million. View Theravance Biopharma's earnings history.

What price target have analysts set for TBPH?

5 brokers have issued twelve-month price objectives for Theravance Biopharma's stock. Their forecasts range from $18.00 to $55.00. On average, they expect Theravance Biopharma's stock price to reach $36.00 in the next year. This suggests a possible upside of 54.6% from the stock's current price. View analysts' price targets for Theravance Biopharma.

Has Theravance Biopharma been receiving favorable news coverage?

Headlines about TBPH stock have been trending very negative this week, InfoTrie Sentiment Analysis reports. InfoTrie identifies negative and positive media coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Theravance Biopharma earned a daily sentiment score of -3.3 on InfoTrie's scale. They also gave headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the stock's share price in the immediate future. View the latest news aboutTheravance Biopharma.

Are investors shorting Theravance Biopharma?

Theravance Biopharma saw a increase in short interest during the month of February. As of February 28th, there was short interest totaling 3,370,000 shares, an increase of 6.0% from the February 13th total of 3,180,000 shares. Based on an average daily volume of 417,200 shares, the days-to-cover ratio is currently 8.1 days. Approximately 8.0% of the company's shares are sold short. View Theravance Biopharma's Current Options Chain.

Who are some of Theravance Biopharma's key competitors?

What other stocks do shareholders of Theravance Biopharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Theravance Biopharma investors own include Gilead Sciences (GILD), Bausch Health Companies (BHC), Exelixis (EXEL), Teva Pharmaceutical Industries (TEVA), Johnson & Johnson (JNJ), AT&T (T), Immunomedics (IMMU), SCYNEXIS (SCYX), Verizon Communications (VZ) and Clovis Oncology (CLVS).

Who are Theravance Biopharma's key executives?

Theravance Biopharma's management team includes the following people:
  • Mr. Rick E. Winningham, Chairman & CEO (Age 59)
  • Mr. Bradford J. Shafer, Exec. VP, Gen. Counsel & Sec. (Age 59)
  • Dr. Shehnaaz Suliman M.D., M.Phil., M.B.A., Sr. VP of Corp. Devel. & Strategy (Age 46)
  • Dr. Brett K. Haumann, Sr. VP of Clinical Devel. & Chief Medical Officer (Age 49)
  • Mr. Vijay Sabesan, Sr. VP of Technical Operations

What is Theravance Biopharma's stock symbol?

Theravance Biopharma trades on the NASDAQ under the ticker symbol "TBPH."

How do I buy shares of Theravance Biopharma?

Shares of TBPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Theravance Biopharma's stock price today?

One share of TBPH stock can currently be purchased for approximately $23.29.

How big of a company is Theravance Biopharma?

Theravance Biopharma has a market capitalization of $1.47 billion and generates $73.41 million in revenue each year. The biopharmaceutical company earns $-236,460,000.00 in net income (profit) each year or ($4.25) on an earnings per share basis. Theravance Biopharma employs 363 workers across the globe. View additional information about Theravance Biopharma.

What is Theravance Biopharma's official website?

The official website for Theravance Biopharma is http://www.theravance.com/.

How can I contact Theravance Biopharma?

Theravance Biopharma's mailing address is UGLAND HOUSE SOUTH CHURCH STREET, GEORGE TOWN E9, KY1-1104. The biopharmaceutical company can be reached via phone at 650-808-6000 or via email at [email protected]

This page was last updated on 4/7/2020 by MarketBeat.com Staff

Featured Article: Municipal Bonds

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel